Fungal-host-microbiota interactions

Candida albicans and Lactobacillus rhamnosus interacting on intestinal epithelial cells

Candida albicans is a regular member of the intestinal microbiota in the majority of the human population, but can also colonize the oral or vaginal mucosa. In such environments this yeast lives as a harmless commensal in cohabitation with the bacterial microbiota without inducing competitive interactions or immune responses detrimental to its survival. However, specific conditions such as a dysbalanced microbiome, suppression of the immune system, and an impaired epithelial barrier function can predispose for oral or vulvovaginal infections or even invasive, mostly nosocomial, C. albicans infections.

In particular, the association between the use of antibiotics and C. albicans infection illustrates that bacterial microbiota is crucial in preventing fungal pathogenesis. Furthermore, murine models and patient studies demonstrate that removal of protective bacteria is a major predisposing factor favoring a commensal-to-pathogen shift and initiation of disease.

We are investigating bacteria that antagonize the pathogenicity of C. albicans and which may contribute to keeping this opportunistic pathogen in a commensal state. We use genome-wide transcription profiling techniques, metabolomics, and state-of-the-art in vitro infection models to uncover the molecular interactions between C. albicans and bacteria that antagonize its pathogenicity. Using organ-on-chip models that integrate epithelial cells, immune cells, and a bloodstream-like compartment, the three-way interaction between the fungus, host, and members of the bacterial microbiota is investigated. We also closely collaborate with the Junior Research Group Adaptive Pathogenicity Strategies on how these interactions influence immune recognition.

Also, recently, it has been described that the bacterial Type 6 Secretion System (T6SS), such as the one from the bacterium Serratia marcescens, can directly act against fungi. This might have a key role in determining the fate of a fungal infection. We just started investigating how anti-fungal T6SS can influence the nature and outcome of a bacterial-fungal co-colonization or co-infection of the mammalian gut.

Staff

Osama Elshafee
Tim Schille
Jakob Sprague
Marisa Valentine

Publications

Alonso-Roman R, Mosig AS, Figge MT, Papenfort K, Eggeling C, Schacher FH, Hube B#, Gresnigt MS (2024) Organ-on-chip models for infectious disease research. Nat Microbiol 9(4), 891-904. (Review)
Kaden T, Alonso-Román R, Stallhofer J, Gresnigt MS, Hube B, Mosig AS (2024) Leveraging organ-on-chip models to investigate host-microbiota dynamics and targeted therapies for inflammatory bowel disease. Adv Healthc Mater [Epub ahead of print] (Review)
Katsipoulaki M, Stappers MHT, Malavia-Jones D, Brunke S, Hube B, Gow NAR (2024) Candida albicans and Candida glabrata: global priority pathogens. Microbiol Mol Biol Rev 88(2), e0002123. (Review)
Sala A, Ardizzoni A, Spaggiari L, Vaidya N, van der Schaaf J, Rizzato C, Cermelli C, Mogavero S, Krüger T, Himmel M, Kniemeyer O, Brakhage AA, King BL, Lupetti A, Comar M, de Seta F, Tavanti A, Blasi E, Wheeler RT, Pericolini E (2023) A new phenotype in Candida-epithelial cell interaction distinguishes colonization-versus culvovaginal candidiasis-associated strains. mBio 14(2), e0010723.
Alonso-Roman R, Last A, Mirhakkak MH, Sprague JL, Möller L, Großmann P, Graf K, Gratz R, Mogavero S, Vylkova S, Panagiotou G, Schäuble S, Hube B, Gresnigt MS (2022) Lactobacillus rhamnosus colonisation antagonizes Candida albicans by forcing metabolic adaptations that compromise pathogenicity. Nat Commun 13(1), 3192.
Mogavero S, Höfs S, Lauer AN, Müller R, Brunke S, Allert S, Gerwien F, Groth S, Dolk E, Wilson D, Gutsmann T, Hube B (2022) Candidalysin is the hemolytic factor of Candida albicans. Toxins (Basel) 14(12), 874.
Richardson JP, Brown R, Kichik N, Lee S, Priest E, Mogavero S, Maufrais C, Wickramasinghe DN, Tsavou A, Kotowicz NK, Hepworth OW, Gallego-Cortés A, Ponde NO, Ho J, Moyes DL, Wilson D, D'Enfert C, Hube B, Naglik JR (2022) Candidalysins are a new family of cytolytic fungal peptide toxins. mBio 13(1), e0351021.
Alonso-Monge R, Gresnigt MS, Román E, Hube B, Pla J (2021) Candida albicans colonization of the gastrointestinal tract: A double-edged sword. PLOS Pathog 17(7), e1009710.
d'Enfert C, Kaune AK, Alaban LR, Chakraborty S, Cole N, Delavy M, Kosmala D, Marsaux B, Fróis-Martins R, Morelli M, Rosati D, Valentine M, Xie Z, Emritloll Y, Warn PA, Bequet F, Bougnoux ME, Bornes S, Gresnigt MS, Hube B, Jacobsen ID, Legrand M, Leibundgut-Landmann S, Manichanh C, Munro CA, Netea MG, Queiroz K, Roget K, Thomas V, Thoral C, Van den Abbeele P, Walker AW, Brown AJP (2021) The impact of the Fungus-Host-Microbiota interplay upon Candida albicans infections: current knowledge and new perspectives. FEMS Microbiol Rev 45(3), fuaa060. (Review)
Last A, Maurer M, Mosig AS, Gresnigt MS, Hube B (2021) In vitro infection models to study fungal-host interactions. FEMS Microbiol Rev 45(5), fuab005. (Review)

Funding